Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses optimization of therapies in breast cancer, including the development of escalation and de-escalation studies in order to minimize toxicity and improve efficacy in patients with breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
